STAT

SEPTEMBER 8, 2024

News that a person in Missouri contracted H5 bird flu despite having no known contact with infected animals or birds — in other words, no evident route of infection — raises pressing questions public health officials are surely scurrying to answer. The rationale for that urgency is this: An unexplained H5 infection raises the possibility of person-to-person spread of a flu virus that has never before circulated in humans, and to which people would not have immunity.

Immunization 145

Immunization 145

Fierce Pharma

SEPTEMBER 8, 2024

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.

141

141

STAT

SEPTEMBER 8, 2024

SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in billions of dollars to the pharma giant. But detailed data presented by Summit Therapeutics on Sunday demonstrated that the company’s experimental therapy has done what no other has done before: beat Keytruda in a head-to-head late-stage trial in lung cancer.

145

145

pharmaphorum

SEPTEMBER 8, 2024

CDC reports the first-ever US case of an H5 strain of avian influenza without a known occupational exposure to sick or infected animals

119

119

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

SEPTEMBER 8, 2024

A busy medical student, Vanessa Apea wasn’t her usual energetic self. So she dragged herself to the doctor to get checked and have her blood drawn. A week later, she received a call telling her to return to the clinic; it was urgent. When she arrived, the doctor asked if she had a family history of blood or genetic disorders. Was she having shortness of breath?

141

141

pharmaphorum

SEPTEMBER 8, 2024

Results of Ideate-Lung01 trial at WCLC back up MSD and Daiichi Sankyo's decision to move anti-B7-H3 ADC I-Dxd into phase 3 for small cell lung cancer

111

111

Pharmaceutical Technology

SEPTEMBER 8, 2024

Botanical Solution Inc.

59

59

The Guardian - Pharmaceutical Industry

SEPTEMBER 8, 2024

Experts call for more research into ‘off-label’ medications, and supply chain alternatives not driven by profit motive Get our breaking news email , free app or daily news podcast Several crucial medicines for pregnant women are in shortage in Australia because of a “perfect storm”, experts warn, whereby the only drugs registered as safe for pregnancy are old and less profitable to pharmaceutical companies discontinuing their distribution amid manufacturing disruptions since the pandemic.

Pharmaceutical Companies 57

Pharmaceutical Companies Pharmaceutical Companies Labelling 57

The Honest Apothecary

SEPTEMBER 8, 2024

A post on my preference for connections rather than simple comments

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Mantle Cell Lymphoma.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

BioPharm

SEPTEMBER 8, 2024

Weighing development costs/resources and performance benefits is essential.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Relapsed Acute Myeloid Leukemia.

52

52

The Honest Apothecary

SEPTEMBER 8, 2024

One of the convictions I had as I began to re-imagine my blog is that it would be an entirely non-monetized form of expression. For some, blogging is actually a source of significant income, and I see nothing wrong with this. For others, writing is a way to drive potential customers to their “paid” product.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

The Honest Apothecary

SEPTEMBER 8, 2024

Another important decision I had to make, as I began to re-imagine The Honest Apothecary blog, was about the posting cadence I intend to keep up. To put it in more pharmaceutical terms: What would the dosing frequency be? QD? QOD? PRN? Those are pharmacy shorthand for daily, every other day, or as needed.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Pearson Syndrome.

52

52

The Honest Apothecary

SEPTEMBER 8, 2024

“So you see Jason,” said the man we’ll call “Steve”, to me as we sipped on our coffees in the cafeteria, “Tonya is a great individual contributor. She knows her job well, better than most.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Subacute Necrotizing Encephalomyelopathy (Leigh Disease).

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

SEPTEMBER 8, 2024

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

Sonidegib phosphate is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Non-Small Cell Lung Cancer.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia.

52

52

Pharmaceutical Technology

SEPTEMBER 8, 2024

SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

RD-129 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Autoimmune Disorders.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

MAR-001 is under clinical development by Marea Therapeutics and currently in Phase II for Hypertriglyceridemia.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Autoimmune Disorders.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Inflammation.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

Chenodiol is under clinical development by Mirum Pharmaceuticals and currently in Pre-Registration for Cerebrotendinous Xanthomatosis.

40

40

Pharmaceutical Technology

SEPTEMBER 8, 2024

FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Cervical Cancer.

40

40